← Back to Home

CGuard Prime Receives FDA Approval for Transcarotid Revascularization, Adding a Stent Option

The approval gives patients at high risk for carotid surgery another stent option. The 50-patient trial supporting the approval reported no major events such as stroke within 30 days, but its size and follow-up duration still limit assessments of long-term safety.

By SURL BioNews

Treating carotid artery stenosis requires not only opening the vessel but also guarding against embolic risks during the intervention. InspireMD announced on November 12 that its CGuard Prime transcarotid stent system had received approval from the U.S. Food and Drug Administration (FDA) for use in transcarotid artery revascularization (TCAR), adding an option for some patients who need carotid blood flow restored.

In an 8-K filing submitted to the U.S. Securities and Exchange Commission on the same day, the company formally disclosed the approval of this premarket approval supplement under Item 8.01. The indication covers patients who require carotid revascularization, are at higher risk of adverse events from carotid endarterectomy, and meet the conditions specified in the labeling. The device must be used with an embolic protection system specified in the labeling.

The system uses an 80-centimeter delivery device, while the stent itself consists of a self-expanding nitinol structure covered with permanent MicroNet micromesh. The design aims to provide an additional barrier through the micromesh while opening the vessel. Whether this design translates into better clinical outcomes than other stents still requires comparative evidence.

CGUARDIANS II, the study supporting the approval, was a prospective, single-arm trial conducted at 11 study centers in the United States. It enrolled 50 patients at high surgical risk and used the device with the ENROUTE Transcarotid Neuroprotection System. According to the company's announcement, acute device success was 100%, with no deaths, strokes, myocardial infarctions, or stent thromboses reported within 30 days. Stents in all evaluable patients also remained patent.

These results provide evidence of short-term performance, but the 50-patient, single-arm study had no randomized control group and could not adequately capture rare risks. The absence of these events within 30 days does not mean that subsequent risk is zero, nor is it sufficient to establish an advantage in long-term stroke prevention. The product labeling still lists risks including stroke, death, thrombosis, vessel dissection, and puncture-site complications.

For InspireMD, the approval allows the company to enter the TCAR market using an existing, approved protection system. Its own SwitchGuard Neuroprotection System remains under clinical investigation and has not yet been approved for sale in the United States. Securing a new indication for the stent and completing development of an entire proprietary platform therefore remain two distinct stages.

References

  1. InspireMD / SEC
  2. InspireMD / U.S. Securities and Exchange Commission